Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.97 |
| ▸ | RAB9A | P51151 | 7/20 | 0.97 |
| ▸ | MEN1 | O00255 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.97 |
| ▸ | TP53 | P04637 | 6/20 | 0.97 |
| ▸ | HPGD | P15428 | 6/20 | 0.97 |
| ▸ | NPC1 | O15118 | 6/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.97 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.97 |
| ▸ | POLB | P06746 | 3/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.97 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.97 |
| ▸ | MAOA | P21397 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Genistein SCHEMBL552594 | 0.98 | MAPT (0.94) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL19166 | 0.98 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL29352944 | 0.98 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL554056 | 0.98 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL551801 | 0.97 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL31168045 | 0.97 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL551352 | 0.97 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL551449 | 0.97 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL38650814 | 0.97 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| Genistein SCHEMBL29586487 | 0.97 | MAPT (0.97) | MAPTSMN1; SMN2ALDH1A1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373326-B1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTUCALS AB (SE) | 2016-03-09 | — | — | EP | claimed |
| US-9012495-B2 | Crystalline forms of genistein | AXCENTUA PHARMACEUTICALS AB (SE) | 2015-04-21 | — | — | US | claimed |
| US-20120035253-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTICALS AB (SE) | 2012-02-09 | — | — | US | claimed |
| CN-102292097-A | Crystalline forms of genistein | — | 2011-12-21 | — | — | CN | claimed |
| EP-2373326-A1 | CRYSTALLINE FORMS OF GENISTEIN | Axcentua Pharmaceutucals AB (SE) | 2011-10-12 | — | — | EP | claimed |
| WO-2010068861-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTUCALS AB (SE) | 2010-06-17 | — | — | WO | claimed |
| US-20240058298-A1 | GENISTEIN FOR USE IN THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | DELTA 4 GMBH (AT) | 2024-02-22 | — | — | US | disclosed |
| EP-4255415-A1 | GENISTEIN FOR USE IN THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Delta 4 GmbH (AT) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022117864-A1 | GENISTEIN FOR USE IN THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | DELTA 4 GMBH (AT) | 2022-06-09 | — | — | WO | disclosed |
| CN-104860913-B | The crystal form of genistein | 艾克赛特药品有限公司 | 2018-05-04 | — | — | CN | disclosed |
| US-20170202932-A1 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2017-07-20 | — | — | US | disclosed |
| US-9492425-B2 | Crystalline forms of genistein | AXCENTUA PHARMACEUTICALS AB (SE) | 2016-11-15 | — | — | US | disclosed |
| US-9492425-B2 | Crystalline forms of genistein | AXCENTUA PHARMACEUTICALS AB (SE) | 2016-11-15 | — | — | US | disclosed |
| WO-2014005186-A1 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2014-01-09 | — | — | WO | disclosed |
| US-20120035253-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTICALS AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035253-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTICALS AB (SE) | 2012-02-09 | — | — | US | disclosed |
| CN-102292097-A | Crystalline forms of genistein | — | 2011-12-21 | — | — | CN | disclosed |
| CN-102292097-A | Crystalline forms of genistein | — | 2011-12-21 | — | — | CN | disclosed |
| EP-2373326-A1 | CRYSTALLINE FORMS OF GENISTEIN | Axcentua Pharmaceutucals AB (SE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010068861-A1 | CRYSTALLINE FORMS OF GENISTEIN | AXCENTUA PHARMACEUTUCALS AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035253-A1 | CRYSTALLINE FORMS OF GENISTEIN | SHBG, GLS, KLK3 | MAPT 1349/4885SMN1; SMN2 4151/4885ALDH1A1 4858/4885 |
| US-20240058298-A1 | GENISTEIN FOR USE IN THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | REN, GLS, AQP3 | MAPT 2828/4885SMN1; SMN2 3699/4885ALDH1A1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.